N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide manufacturers
- MGH-CP1
-
- $34.00
-
2026-07-17
- CAS:896657-58-2
- Purity: 99.76%
- Supply Ability: 10g
|
| | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide Basic information |
| Product Name: | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide | | Synonyms: | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide;2-((1H-1,2,4-Triazol-5-yl)thio)-N-(4-(adamantan-1-yl)phenyl)acetamide;N-?[4-?(1-?Adamantyl)?phenyl]?-?2-?(4H-?1,?2,?4-?triazol-?3-?ylsulfanyl)?acetamide;MGH CP1,Lats1/2 deletion,Myc,MGHCP1,TEAD auto-palmitoylation,Apoptosis,Epithelial,MGH-CP1,inhibit,Inhibitor,MGH-CP-1;MGH-CP1, 10 mM in DMSO;MGH-CP1 ,S9735 | | CAS: | 896657-58-2 | | MF: | C20H24N4OS | | MW: | 368.49576 | | EINECS: | 816-922-9 | | Product Categories: | | | Mol File: | 896657-58-2.mol | ![N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide Structure](CAS/20200401/GIF/896657-58-2.gif) |
| | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide Chemical Properties |
| storage temp. | 4°C, away from moisture and light | | form | Solid | | color | White to off-white | | InChI | InChI=1S/C20H24N4OS/c25-18(11-26-19-21-12-22-24-19)23-17-3-1-16(2-4-17)20-8-13-5-14(9-20)7-15(6-13)10-20/h1-4,12-15H,5-11H2,(H,23,25)(H,21,22,24) | | InChIKey | UUKXOVBCMOZQNC-UHFFFAOYSA-N | | SMILES | C(NC1=CC=C(C23CC4CC(CC(C4)C2)C3)C=C1)(=O)CSC1NC=NN=1 |
| | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide Usage And Synthesis |
| Uses | N-[4-(1-Adamantyl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide acts as a TEAD transcription factor autopalmitoylation inhibitor which may be a therapeutical treatment for certain cancers. | | in vivo | MGH-CP1 (75mg/kg; PO; daily, for 2 weeks) inhibits the palmitoylation of TEAD proteins in the intestinal epithelium in wild-type mice, but inhibits upregulation of the TEAD target genes, CTGF and ANKRD1, in Lats1/2 KO mice intestine[1]. | Animal Model: | Mice (induced high-dose Cre recombination by intraperitoneal injection of 120mg/kg Tamoxifen for two consecutive days)[1] | | Dosage: | 75 mg/kg | | Administration: | PO; daily, for 2 weeks | | Result: | Effectively inhibited the palmitoylation of TEAD proteins in the intestinal epithelium in wild-type mice, but effectively inhibited upregulation of the TEAD target genes, CTGF and ANKRD1, in Lats1/2 KO mice intestine. |
|
| | N-[4-(adamantan-1-yl)phenyl]-2-(4H-1,2,4-triazol-3-ylsulfanyl)acetamide Preparation Products And Raw materials |
|